These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 18528888

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [Abstract] [Full Text] [Related]

  • 3. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 4. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
    Lau YK, Chadha MK, Litwin A, Trump DL.
    J Hematol Oncol; 2008 Nov 05; 1():21. PubMed ID: 18986533
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
    Mansueto G, Longo F.
    Recenti Prog Med; 2002 Mar 05; 93(3):175-8. PubMed ID: 11942169
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Solitary peritoneal carcinomatosis in prostate cancer].
    Brehmer B, Makris A, Wellmann A, Jakse G.
    Aktuelle Urol; 2007 Sep 05; 38(5):408-9. PubMed ID: 17907070
    [Abstract] [Full Text] [Related]

  • 11. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
    Masue N, Hasegawa Y.
    Hinyokika Kiyo; 2007 Feb 05; 53(2):133-5. PubMed ID: 17352166
    [Abstract] [Full Text] [Related]

  • 12. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness.
    Akaza H.
    Cancer Sci; 2011 Jan 05; 102(1):51-6. PubMed ID: 21091846
    [Abstract] [Full Text] [Related]

  • 13. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
    Nemoto K, Tomita Y.
    Scand J Urol Nephrol; 2007 Jan 05; 41(6):558-60. PubMed ID: 17853028
    [Abstract] [Full Text] [Related]

  • 14. Combined androgen blockade: an update.
    Klotz L.
    Urol Clin North Am; 2006 May 05; 33(2):161-6, v-vi. PubMed ID: 16631454
    [Abstract] [Full Text] [Related]

  • 15. Locally advanced prostate cancer treated with radiotherapy and androgen deprivation.
    Kirby R.
    Nat Clin Pract Urol; 2005 Jun 05; 2(6):304-8. PubMed ID: 16474813
    [Abstract] [Full Text] [Related]

  • 16. Prostate cancer tissue is masked by bicalutamide: a case report.
    Ellinger J, Bastian PJ, Biermann K, Schmidt ME, Textor J, Bollmann D, Zhou H, Müller SC.
    Eur J Med Res; 2007 May 29; 12(5):212-5. PubMed ID: 17513193
    [Abstract] [Full Text] [Related]

  • 17. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
    Spitz IM, Chertin B, Fridmans A, Farkas A, Belanger A, Hartman H, Labrie F.
    Prostate Cancer Prostatic Dis; 2009 May 29; 12(1):100-3. PubMed ID: 18574491
    [Abstract] [Full Text] [Related]

  • 18. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer.
    Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, Marzi S, Landoni V, Fowler J, Strigari L.
    Int J Radiat Oncol Biol Phys; 2010 Sep 01; 78(1):11-8. PubMed ID: 20047800
    [Abstract] [Full Text] [Related]

  • 19. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
    Lloyd A, Penson D, Dewilde S, Kleinman L.
    Prostate Cancer Prostatic Dis; 2008 Sep 01; 11(2):153-9. PubMed ID: 17637761
    [Abstract] [Full Text] [Related]

  • 20. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
    Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford ED, Southwest Oncology Group.
    Cancer; 2008 Jun 01; 112(11):2393-400. PubMed ID: 18383517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.